Moore, M. Gordon et al., "A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors," European Journal of Cancer, vol. 69, article S35, 2016.Jimeno A, Moore K, Gordon M, et al.A first-in-man phase 1a study of the bispeci...
Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor. This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients.DesignA 3 + 3 dose escalation design was used followed by the t...